Strides Arcolab Ltd has announced having received tentative approvals from the US Food and Drug Administration for two new drug applications (NDA) for fixed dose combination of Lamivudine / Stavudine 150mg / 40 mg Tablets and Lamivudine / Stavudine 150 / 40mg tablets co-packaged with Nevirapine 200mg Tablets.

Both drugs were approved under the expedited review provisions of the 'president's emergency plan for aids relief' (PEPFAR) programme. This takes the total NDAs / ANDAs approvals received to 8 under the PEPFAR program.

Arun Kumar, vice chairman and managing director, Strides Arcolab, said "the two new NDA approvals being key products in the treatment of HIV will provide a fillip to our Aids, TB and Malaria (ATM) initiative"

The Company also partners the Clinton Foundation to ensure availability of affordable quality generic ARVs in least developed countries.